- Home
- UAMY vs CBIO Comparison
UAMY vs CBIO Comparison
Compare UAMY & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- CBIO
- Stock Information
- Founded
- UAMY 1968
- CBIO 2003
- Country
- UAMY United States
- CBIO United States
- Employees
- UAMY N/A
- CBIO N/A
- Industry
- UAMY Metal Fabrications
- CBIO
- Sector
- UAMY Industrials
- CBIO
- Exchange
- UAMY Nasdaq
- CBIO Nasdaq
- Market Cap
- UAMY 316.8M
- CBIO 308.0M
- IPO Year
- UAMY N/A
- CBIO N/A
- Fundamental
- Price
- UAMY $4.54
- CBIO $14.29
- Analyst Decision
- UAMY Strong Buy
- CBIO Strong Buy
- Analyst Count
- UAMY 5
- CBIO 5
- Target Price
- UAMY $3.60
- CBIO $25.60
- AVG Volume (30 Days)
- UAMY 6.3M
- CBIO 98.3K
- Earning Date
- UAMY 08-12-2025
- CBIO 07-31-2025
- Dividend Yield
- UAMY N/A
- CBIO N/A
- EPS Growth
- UAMY N/A
- CBIO N/A
- EPS
- UAMY N/A
- CBIO N/A
- Revenue
- UAMY $25,728,046.00
- CBIO N/A
- Revenue This Year
- UAMY $209.07
- CBIO N/A
- Revenue Next Year
- UAMY $98.95
- CBIO N/A
- P/E Ratio
- UAMY N/A
- CBIO N/A
- Revenue Growth
- UAMY 134.91
- CBIO N/A
- 52 Week Low
- UAMY $0.49
- CBIO $10.83
- 52 Week High
- UAMY $5.13
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- UAMY 64.05
- CBIO 52.92
- Support Level
- UAMY $4.38
- CBIO $13.50
- Resistance Level
- UAMY $5.13
- CBIO $16.00
- Average True Range (ATR)
- UAMY 0.40
- CBIO 0.79
- MACD
- UAMY 0.01
- CBIO 0.16
- Stochastic Oscillator
- UAMY 69.56
- CBIO 39.68
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.